Actus Santé

Les certificats logiciels : au service de la protection des données de santé

ASIP Santé - jeu, 16/12/2021 - 10:38
Les certificats logiciels : au service de la protection des données de santé
Sous-titre
Professionnels de santé, authentifiez-vous en toute sécurité avec des certificats logiciels
photo_certificats_logiciels

Un certificat logiciel est un fichier informatique faisant fonction de pièce d'identité numérique. 
Il permet de garantir à distance l’identité d’une personne physique (un professionnel de santé par exemple) et/ou d’une personne morale (une structure de santé par exemple).

Un certificat logiciel contient des informations sur son propriétaire, certifiées par un tiers de confiance appelé "autorité de certification". Il permet 3 fonctionnalités principales :

  • l’authentification;
  • la signature électronique;
  • la sécurisation / le chiffrement des données.

L’Agence du Numérique en Santé est l’autorité de certification du domaine de la santé. Elle délivre des certificats logiciels pour sécuriser les échanges de données de santé informatisées entre les professionnels de santé exerçant en ville, à l’hôpital et dans les établissements médico-sociaux.

L’Agence du Numérique en Santé propose actuellement 4 offres de certificats logiciels :

  • Certificat de personne morale Serveur
  • Certificat de personne morale Organisation
  • Certificat de personne physique Professionnel
  • Certificat de personne physique Professionnel de Santé (PS)
     
Matrice des offres à commander en fonction des projets / usages */ /*-->*/ Projet / Usage Offre Certificat Logiciel DMP ORG AUTH_CLI
ORG SIGN MS Santé SERV SSL ROR (Répertoire Opérationnel des Ressources) ORG AUTH_CLI
OU SERV SSL PFLAU (Plateforme de Localisation des Appels d’Urgence) SERV SSL
ORG AUTH_CLI Annuaire AMC (Assurance Maladie Complémentaire) ORG AUTH_CLI RPPS (partenaires) ORG AUTH_CLI
ORG SIGN Annuaire Santé (RASS) ORG AUTH_CLI PRATIC ORG AUTH_CLI Dossier Pharmaceutique (DP) ORG AUTH_CLI Diapason SERV SSL
ORG AUTH_CLI ROC ORG SIGN PSIG (Portail des Signalements Sanitaires) SERV SSL
ORG AUTH_CLI SPEI (Prescription électronique)
GIE SESAM VITALE ORG SIGN eCRF (cahier d'observations électroniques) plateforme de recherches cliniques ORG AUTH_CLI France TAVI- Clingrid (implants Cardiologie) ORG AUTH_CLI Signature de flux de facturation ORG SIGN
Catégories: Actus Santé

Concours de recrutement de bibliothécaires (session 2021)

MESRI - Tous les rapports - il y a 36 min 22 sec

Rapport du jury des concours de recrutement de bibliothécaires, session 2021 (concours externe, externe spécial et interne). Fonction publique d'État et Ville de Paris : cadre général et données statistiques, épreuves et résultats, remarques et conseils.

Catégories: Actus Santé

Leading CNRS project on hybrid AI launched in Singapore

CNRS News - il y a 42 min 1 sec
A vast collaborative project on hybrid artificial intelligence, led by the CNRS's subsidiary in Singapore and allocated a budget of €35 million over five years, will begin in late 2021.
Catégories: Actus Santé

Activité d’un membre AMADES – Pierrine Didier – « Les temps du confinement, de l’ordinaire et du domestique : une recherche participative sur le vif par le recueil de témoignages écrits »

Journée d’étude « Les vécus du confinement, un an après »

Direction scientifique : Bernard Cherubini

 25 Juin 2021 à partir de 13h30

Format webinaire – journée d’étude en ligne – Inscriptions obligatoires via ce lien

L’Observatoire des politiques publiques en situation d’épidémie et post-épidémique (OPPEE) fait partie des vingt projets en SHS retenus par la mission COVID de l’université de Bordeaux en juin 2020. Un an après, nous avons souhaité réunir des chercheurs investis sur la thématique du confinement depuis la première période de confinement, venus de plusieurs villes de l’hexagone et de l’outre-mer, pour nous faire part de leurs observations et de leurs analyses.

Cette journée d’étude confiée à l’IRM-CMRP vient prendre place dans les deux premiers axes du
programme de l’OPPEE consacrés aux politiques sanitaires et aux politiques de santé publique. Le vécu du confinement est ici limité à des enquêtes portant sur la population en général, mais aussi sur la population étudiante, en s’intéressant aux vécus des professionnels durant ces périodes au niveau de plusieurs secteurs comme la médecine générale, la médecine hospitalière, voire la médecine préventive universitaire.

Consulter le programme

Catégories: Actus Santé

Survey: Help shape the future of ESCAIDE

ECDC has recently launched an evaluation that will inform the future of the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE).

Catégories: Actus Santé

Lancement d'un appel à projets national relatif à l'activité de dépistage du VIH, du VHB ou du VHC en milieu associatif

De nombreuses personnes porteuses du VIH, du VHB ou du VHC ne connaissent pas leur statut sérologique et sont dépistées à un stade avancé de l'infection.

Suivant les recommandations de la Haute Autorité de Santé et du Conseil national du sida et des hépatites virales chroniques (CNSHVC), le ministère des solidarités et de la santé poursuit son engagement en faveur du dépistage de l'infection à VIH et des hépatites virales B et C , afin de dépister plus précocement les personnes infectées, en complément du dépistage par sérologie.

L'objectif est de dépister des personnes exposées au risque de VIH, d'hépatite C et/ou d'hépatite B mais qui ne viennent pas dans le système classique de prévention et dépistage. Il s'agit d'aller vers ces populations dans une démarche communautaire.

Le ministère des solidarités et de la santé, en lien avec la Caisse nationale de l'assurance maladie, lance le 22 juin 2021 un appel à projets visant à soutenir l'activité de dépistage rapide par TROD VIH, TROD VHC, TROD VHB et par autotest VIH réalisée par les associations au plus près des populations les plus exposées au risque.

Date limite de soumission : 12 septembre 2021.

Cet appel à projets a pour objectif de soutenir financièrement l'offre de dépistage communautaire du VIH et/ou VHC et/ou VHB assurée par des associations impliquées dans la prévention sanitaire ou la réduction des risques et des dommages associés à la consommation de substances psychotropes.

Il s'adresse aux associations qui participent déjà au dispositif de dépistage communautaire par TROD VIH et ou VHC, mais aussi à de nouvelles associations habilitées qui souhaitent rejoindre le dispositif, que ce soit pour réaliser des dépistages par TROD VIH et/ou par TROD VHC et/ou par TROD VHB. L'appel à projets permet en outre d'accompagner financièrement les associations volontaires pour la délivrance d'autotests de VIH.

La date limite de soumission et d'envoi d'un dossier de candidature à la direction générale de santé est fixée au 12 septembre 2021 à minuit.


Pour tout renseignement complémentaire, merci de contacter : sp2-aap-trod-2021@sante.gouv.fr

Documents téléchargeables pour constituer votre dossier :

pdf Cahier des charges de l'appel à projets 2021 Téléchargement (870.9 ko)
xlsx Annexe 1 (Format excel) Téléchargement (10.9 ko)
docx Dossier de candidature (Format word) Téléchargement (32.1 ko)
docx Fiche de demande de mise à disposition d'autotests VIH Téléchargement (17.6 ko)



Liens utiles

- Arrêté du 16 juin 2021 modifiant l'arrêté du 1er août 2016 modifié déterminant la liste des tests, recueils et traitements de signaux biologiques qui ne constituent pas un examen de biologie médicale, les catégories de personnes pouvant les réaliser et les conditions de réalisation de certains de ces tests, recueils et traitements de signaux biologiques

- Arrêté du 16 juin 2021 fixant les conditions de réalisation des tests rapides d'orientation diagnostique de l'infection par les virus de l'immunodéficience humaine (VIH 1 et 2) et des infections par les virus de l'hépatite C (VHC) et de l'hépatite B (VHB), en milieu médico-social ou associatif et autres centres et établissements autorisés

Catégories: Actus Santé

La newsletter des coordinations hospitalières

Agence de la Biomédecine - il y a 6 heures 29 min
La newsletter de l'Agence de la biomédecine dédiée aux coordinations hospitalières

L'Agence de la biomédecine a mis en place une lettre d'information électronique sur le don d'organes et de tissus à destination des coordinations hospitalières de prélèvement d'organes et de tissus. L'objectif des 3 numéros annuels est d'informer sur les actions et les outils de communication mis en place par l'Agence de la biomédecine dans ces domaines, de partager des actualités et des informations scientifiques, et de donner la parole aux coordinations hospitalières.

Initiatives de 2016 à 2020
Catégories: Actus Santé

Consommer une alimentation riche en caroténoïdes diminue les risques de développer une DMLA

INSERM - Salle de presse - il y a 7 heures 1 min
Une nouvelle étude publiée par des chercheurs de l’Inserm et de l’université de Bordeaux au Centre de recherche Bordeaux Population Health met en évidence de façon inédite une association entre les caroténoïdes circulants – des pigments végétaux protecteurs pour la rétine – et une réduction du risque de développer une forme avancée de DMLA.
Catégories: Actus Santé

Population disruption: estimating changes in population distribution in the UK during the COVID-19 pandemic

Mobility data have demonstrated major changes in human movement patterns in response to COVID-19 and associated interventions in many countries. This can involve sub-national redistribution, short-term relocations as well as international migration. In this paper, we combine detailed location data from Facebook measuring the location of approximately 6 million daily active Facebook users in 5km2 tiles in the UK with census-derived population estimates to measure population mobility and redistribution. We provide time-varying population estimates and assess spatial population changes with respect to population density and four key reference dates in 2020 (First lockdown, End of term, Beginning of term, Christmas). We also show how the timing and magnitude of observed population changes can impact the size of epidemics using a deterministic model of COVID-19 transmission. We estimate that between March 2020 and March 2021, the total population of the UK has declined and we identify important spatial variations in this population change, showing that low-density areas have experienced lower population decreases than urban areas. We estimate that, for the top 10% highest population tiles, the population has decreased by 6.6%. Further, we provide evidence that geographic redistributions of population within the UK coincide with dates of non-pharmaceutical interventions including lockdowns and movement restrictions, as well as seasonal patterns of migration around holiday dates. The methods used in this study reveal significant changes in population distribution at high spatial and temporal resolutions that have not previously been quantified by available demographic surveys in the UK. We found early indicators of potential longer-term changes in the population distribution of the UK although it is not clear how these changes may persist after the COVID-19 pandemic.
Catégories: Actus Santé

European Innovation Council Fund: equity investments surpass €500 million in breakthrough innovations

EU Newsroom - Research and innovation - il y a 16 heures 25 min

European Commission Press release Brussels, 24 Jun 2021 The European Commission has announced today the second round of direct equity investment through the European Innovation Council (EIC) Fund.

Catégories: Actus Santé

Reduction in severity of all-cause gastroenteritis requiring hospitalisation in children vaccinated against rotavirus in Malawi

Background: Rotavirus is the major cause of severe gastroenteritis in children aged <5 years. Introduction of Rotarix rotavirus vaccine (RV1) in Malawi in 2012 has reduced rotavirus-associated hospitalisations and diarrhoeal mortality. However, RV1 impact on gastroenteritis severity remains unknown. We conducted a hospital-based surveillance study to assess RV1 impact on gastroenteritis severity in children aged <5 years, in Malawi. Methods: Stool samples were collected from children hospitalised with acute gastroenteritis from December 2011 to October 2019. Gastroenteritis severity was determined using Ruuska and Vesikari scores. Rotavirus was detected in stool using Enzyme Immunoassay. Rotavirus genotypes were determined using nested RT-PCR. Associations between RV1 vaccination and gastroenteritis severity were investigated using adjusted linear regression. Results: In total, 3,159 children were recruited. After adjusting for Mid-Upper Arm Circumference, age, weight, gender and receipt of other vaccines, all-cause gastroenteritis severity scores were 2.21 units lower (95% CI 1.85, 2.56; p<0.001) among RV1-vaccinated (n=2,224) compared to RV1-unvaccinated children (n=935); the decrease was comparable between rotavirus-positive and rotavirus-negative cases in all age groups. The reduction in severity score was observed against every rotavirus genotype, although the magnitude was smaller among those infected with G12P[6] compared to the remaining genotypes (p=0.011). Other than RV1 vaccination, age was the only variable associated with gastroenteritis severity. Each one-year increment in age was associated with a decrease of 0.43 severity score (95% CI 0.26, 0.60; p<0.001). Conclusion: Our findings provide additional evidence of RV1 impact in a high disease burden, low-income country, lending further support to rotavirus vaccine programme in Malawi.
Catégories: Actus Santé

Genomic evidence for prisons as amplifiers of community tuberculosis epidemics

Prisons are high-incidence settings for tuberculosis around the world, yet the contribution of spillover from prisons in driving community epidemics has not been quantified. We whole genome sequenced 1,152 M. tuberculosis isolates from participants diagnosed with tuberculosis within prisons and in the community in Mato Grosso do Sul, Brazil from 2014 to 2019. By integrating timed phylogenies and detailed location data, we reconstructed probabilistic transmission histories. M. tuberculosis sequences from incarcerated and non-incarcerated people were closely phylogenetically related. We found that 57% of recent community-wide tuberculosis cases were attributable to transmission from individuals with an incarceration history, 2.6% of the population. Further, we find genomic evidence that the prison system disseminates M. tuberculosis genotypes through frequent transfers across the state. This population-wide genomic transmission reconstruction framework can be applied to identify key environments amplifying infectious disease transmission to prioritize public health interventions.
Catégories: Actus Santé

Effect of Electronic Nicotine Delivery Systems on Cigarette Abstinence in Smokers with no Plans to Quit: Exploratory Analysis of a Randomized Placebo-Controlled Trial

Introduction: The extent to which use of electronic nicotine delivery systems (ENDS) for smoking reduction leads to cigarette abstinence in smokers with no plans to quit smoking is unclear. This exploratory analysis examined the effects of ENDS delivering different amounts of nicotine on cigarette abstinence up to 24-week follow-up, in comparison to placebo or a behavioral substitute. Methods: This four-arm parallel-group, randomized placebo-controlled trial took place at two academic medical centers in USA (Penn State Hershey and Virginia Commonwealth University). Participants were current adult smokers (N=520) interested in reducing but not planning to quit. They received brief advice and were randomized to one of four 24-week conditions, receiving either an eGo-style ENDS paired with 0, 8 or 36 mg/ml nicotine liquid (double-blind) or a cigarette-shaped tube, as a cigarette substitute (CS). Self-reported daily cigarette consumption and exhaled carbon monoxide (CO) were measured at all study visits. Outcomes included intent-to-treat, self-reported 7-day cigarette abstinence, biochemically confirmed by exhaled CO at 24 weeks after randomization. Results: At 24 weeks, significantly more participants in the 36 mg/ml condition (14/130, 10.8%) than in the 0 mg/ml condition (1/130, 0.8%) and the CS condition (4/130, 3.1%) were abstinent (relative risk = 14 [95% CI=1.9-104.9] and 3.5 [95% CI=1.2-10.4], respectively). The abstinence rate in the 8 mg/ml condition was 4.6% (6/130). Conclusions: When smokers seeking to reduce smoking tried ENDS, few quit smoking in the short term. However, if smokers continued to use an ENDS with cigarette-like nicotine delivery, a greater proportion completely switched to ENDS, as compared with placebo or a cigarette substitute.
Catégories: Actus Santé

Correlates of Protection against symptomatic and asymptomatic SARS-CoV-2 infection

Background: Although 6 COVID-19 vaccines have been approved by the World Health Organisation as of 7th June 2021, global supply remains limited. An understanding of the immune response associated with protection could facilitate rapid licensure of new vaccines. Methods: Data from a randomised efficacy trial of ChAdOx1 nCoV-19 (AZD1222) vaccine in the UK was analysed to determine the antibody levels associated with protection against SARS-CoV-2. Anti-spike and anti-RBD IgG by multiplex immunoassay, pseudovirus and live neutralizing antibody at 28 days after the second dose were measured in infected and non-infected vaccine recipients. Weighted generalised additive models for binary data were applied to outcome. Cubic spline smoothed log antibody levels, and baseline risk of exposure were the predictor variables with weights applied to account for selection bias in sample processing. Results: Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. Vaccine efficacy of 80% against primary symptomatic COVID-19 was achieved with antibody level of 40923 (95% CI: 16748, 125017) and 63383 (95% CI: 16903, not computed (NC)) for anti-spike and anti-RBD, and 185 (95% CI: NC, NC) and 247 (95% CI: 101, NC) for pseudo- and live-neutralisation assays respectively. Antibody responses did not correlate with overall protection against asymptomatic infection. Conclusions: Correlates of protection can be used to bridge to new populations using validated assays. The data can be used to extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted. More work is needed to assess correlates for emerging variants.
Catégories: Actus Santé

Trends in COVID-19 vaccination intent, determinants and reasons for vaccine hesitancy: results from repeated cross-sectional surveys in the adult general population of Greece during November 2020-June 2021

Background: Vaccine hesitancy is a major barrier to achieve large-scale COVID-19 vaccination. We report trends in vaccination intention and associated determinants from surveys in the adult general population in Greece. Methods: Four cross-sectional phone surveys were conducted in November 2020, February, April and May 2021 on nationally representative samples of adults in Greece. Multinomial logistic regression was used on the combined data of the surveys to evaluate independent predictors of vaccination unwillingness/uncertainty. Results: Vaccination intention increased from 67.6% in November 2020 to 84.8%. in May 2021. Individuals aged 65 years or older were more willing to get vaccinated (May 2021: 92.9% vs. 79.5% in 18-39 years, p<0.001) but between age-groups differences decreased over time. Vaccination intention increased substantially in both sexes, though earlier among men than women and was higher in individuals with postgraduate studies (May 2021: 91.3% vs. 84.0% up to junior high). From multivariable analysis, unwillingness and/or uncertainty to get vaccinated was associated with younger age, female gender (in particular in the April 2021 survey), lower educational level and living with a child [≤]12 years old. Among those with vaccine hesitancy, concerns about vaccine effectiveness declined over time (21.6% in November 2020 vs. 9.6% in May 2021, p=0.014) and were reported more often by men; safety concerns remained stable over time (66.3% in November 2020 vs. 62.1% in May 2021, p=0.658) and were reported more often by women. Conclusions: Vaccination intention increased substantially over time. Tailored communication is needed to address vaccine hesitancy and concerns regarding vaccine safety.
Catégories: Actus Santé

Selective tweeting of COVID-19 articles: Does title or abstract positivity influence dissemination?

Background: Previous research has shown that articles may be cited more frequently on the basis of title or abstract positivity. Whether a similar selective sharing practice exists on Twitter is not well understood. The objective of this study was to assess if COVID-19 articles with positive titles or abstracts were tweeted more frequently than those with non-positive titles or abstracts. Methods: COVID-19 related articles published between January 1st and April 14th, 2020 were extracted from the LitCovid database and all articles were screened for eligibility. Titles and abstracts were classified using a list of positive and negative words from a previous study. A negative binomial regression analysis controlling for confounding variables (2018 impact factor, open access status, continent of the corresponding author, and topic) was performed to obtain regression coefficients, with the p values obtained by likelihood ratio testing. Results: A total of 3752 COVID-19 articles were included. Of the included studies, 44 titles and 112 abstracts were positive; 1 title and 7 abstracts were negative; and 3707 titles and 627 abstracts were neutral. Articles with positive titles had a lower tweet rate relative to articles with non-positive titles, with a regression coefficient of -1.10 (P < .001), while the positivity of the abstract did not impact tweet rate (P = .2218). Conclusion: COVID-19 articles with non-positive titles are preferentially tweeted, while abstract positivity does not influence tweet rate.
Catégories: Actus Santé

Validation of the 4C Deterioration Model for COVID-19 in a UK teaching hospital during Wave 2

The 4C Deterioration model was developed and validated on data collected in UK hospitals until August 26, 2020, but has not yet been validated in the presence of SARS-CoV-2 variants and novel treatment regimens that have emerged subsequently. In this first validation study of the 4C Deterioration model on patients admitted between August 27, 2020 and April 16, 2021 we found, despite a slightly overestimation of risk, that the discrimination (area under the curve 0.75, 95% CI 0.71-0.78) and calibration of the model remained consistent with the development study, strengthening the evidence for adopting this model into clinical practice.
Catégories: Actus Santé

Pages